Correlation between glycosylated haemoglobin and serum lipid profile in patients with type 2 diabetes mellitus in a Tertiary Care Hospital
Keywords:
glycated hemoglobin, dyslipidemia, lipid profileAbstract
Type 2 diabetes mellitus (T2DM) is a chronic disease that develops due to defective insulin secretion and is frequently associated with insulin resistance. T2DM patients are prone to diabetic dyslipidemia, which puts them at risk of developing macrovascular (stroke, peripheral vascular disease and coronary artery disease) and microvascular (nephropathy, neuropathy and retinopathy) diseases. This is a cross sectional study conducted at Tertiary care Teaching Hospital over a period of 1 year. Total 70 patients of Type 2 diabetes mellitus were taken for the study after applying inclusion and exclusion criteria, and after obtaining written and informed consent from them. HbA1c and Fasting Lipid profile: Total cholesterol, Triglycerides, HDL and VLDL cholesterol were measured. In our study, among 70 Type 2 diabetic individuals included in this study, 41 were male and 29 were female. Distribution of Glucose Triad results of FBS, PPBS and HbA1c levels of patients presented as Mean±SD, mean FBS was 173.59±39.64, mean PPBS was 234.59±94.59 and mean HbA1c was 7.78±0.83. Our study accomplished that HbA1c has a direct, significant correlation with total cholesterol, triglyceride, VLDL, and LDL among the lipid profile.
Downloads
References
Singh G, Kumar A. Relationship among HbA1c and lipid profile in Punjabi type 2 diabetic population. J Exercise Sci Physiother. 2011;7:99–102.
Diaf M, Khaled BM. Metabolic profile, nutritional status and determinants of glycaemic control in Algerian type 2 diabetic patients. Kuwait Med J. 2017;49:135–141.
Sreenivas Reddy A, Meera S, William E, Kumar JS. Correlation between glycemic control and lipid profile in type 2 diabetic patients: HbA1c as an indirect indicator of dyslipidemia. Asian J Pharm Clin Res 2014;7(2):153–155.
Deshmukh , et al. Can HbA1c be a marker for cardiovascular risk in type 2 diabetes mellitus. Int J Med Res Rev. 2015;3:419– 423.
Baranwal JK, Lamsal M, Baral N. Association between level of HbA1c and lipid profile in T2DM patients attending diabetic OPD at BPKIHS. Heal Renaiss 2017;13(3):16–23.
Erciyas, F., Taneli, F., Arslan, B., & Uslu, Y. (2004). Glycemic control, oxidative stress, and lipid profile in children with type 1 diabetes mellitus. Archives of medical Research, 35(2), 134-140.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) (2001). Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [spe-cial communication]. JAMA 2001; 285:2486- 2497.
Florkowski, C. (2013). HbA1c as a Diagnostic Test for Diabetes Mellitus - Reviewing the Evidence. Clin Biochem Rev. 34(2), 75–83.
Sarkar S, Meshram A. HbA1c and lipid profile levels in the known type 2 diabetic group in the rural region of Vidarbha, Maharashtra, India. J Evid Based Med Health. 2017;4:1915–1920. doi:10.18410/jebmh/2017/374
Samdani TS, Mitra P, Rahim MA. Relationship of glycated haemoglobin with lipid profile among patients with type 2 diabetes mellitus. BIRDEM Med J. 2017;7:43–47. doi:10.3329/birdem.v7i1.31271
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabet Care. 2010;33:S62–S69. doi:10.2337/dc10-S062
Al Zahidy ZA, Baeshen NR, Alzamil FO, et al. Prevalence of diabetes mellitus among patient presented in Endocrinology Clinic at King Abdul-Aziz Hospital and Oncology Center – Jeddah – 2014. EC Diabet Metab Res. 2017;1(1):2–7.
Deshmukh S, Singh VB, Chetan Kumar H, et al. Can HbA1c be a marker for cardiovascular risk in type 2 diabetes mellitus. Int J Med Res Rev. 2015;3:419–423.
Maahs DM, Ogden LG, Dabelea D, et al. Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication. Diabetologia. 2010;53:2518–2525.
Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med. 1994;121:416–422.
Joshi SR. Saroglitazar for the treatment of dyslipidemia in diabetic patients. Expert Opin Pharmacother. 2015;16:597–606.
Karas RH et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008;8: 69–81
DCCT Research Group. (1996). The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes, 45(10),1289-1298.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
